PortfoliosLab logo
PortfoliosLab logo
Tools
Portfolios
Screeners
Discussions
KYMR vs. XBI
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility

Correlation

The correlation between KYMR and XBI is 0.39, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

KYMR vs. XBI

Last updated Jun 2, 2025

Compare and contrast key facts about Kymera Therapeutics, Inc. (KYMR) and SPDR S&P Biotech ETF (XBI).

XBI is a passively managed fund by State Street that tracks the performance of the S&P Biotechnology Select Industry Index. It was launched on Feb 6, 2006.

Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: KYMR or XBI.

Performance

KYMR vs. XBI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Kymera Therapeutics, Inc. (KYMR) and SPDR S&P Biotech ETF (XBI). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Sharpe Ratio

KYMR:

-0.12

XBI:

-0.39

Sortino Ratio

KYMR:

0.22

XBI:

-0.37

Omega Ratio

KYMR:

1.03

XBI:

0.95

Calmar Ratio

KYMR:

-0.15

XBI:

-0.18

Martin Ratio

KYMR:

-0.45

XBI:

-0.84

Ulcer Index

KYMR:

25.73%

XBI:

13.12%

Daily Std Dev

KYMR:

67.57%

XBI:

27.85%

Max Drawdown

KYMR:

-87.51%

XBI:

-63.89%

Current Drawdown

KYMR:

-66.25%

XBI:

-54.40%

Returns By Period

In the year-to-date period, KYMR achieves a -26.32% return, which is significantly lower than XBI's -12.06% return.

KYMR

YTD

-26.32%

1M

-15.99%

6M

-36.73%

1Y

-7.69%

3Y*

27.59%

5Y*

N/A

10Y*

N/A

XBI

YTD

-12.06%

1M

-5.16%

6M

-20.50%

1Y

-11.02%

3Y*

4.87%

5Y*

-5.15%

10Y*

0.11%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Kymera Therapeutics, Inc.

SPDR S&P Biotech ETF

Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

KYMR vs. XBI — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.
KYMR
The Risk-Adjusted Performance Rank of KYMR is 4242
Overall Rank
The Sharpe Ratio Rank of KYMR is 4444
Sharpe Ratio Rank
The Sortino Ratio Rank of KYMR is 4343
Sortino Ratio Rank
The Omega Ratio Rank of KYMR is 4242
Omega Ratio Rank
The Calmar Ratio Rank of KYMR is 4040
Calmar Ratio Rank
The Martin Ratio Rank of KYMR is 4141
Martin Ratio Rank
XBI
The Risk-Adjusted Performance Rank of XBI is 66
Overall Rank
The Sharpe Ratio Rank of XBI is 66
Sharpe Ratio Rank
The Sortino Ratio Rank of XBI is 66
Sortino Ratio Rank
The Omega Ratio Rank of XBI is 66
Omega Ratio Rank
The Calmar Ratio Rank of XBI is 88
Calmar Ratio Rank
The Martin Ratio Rank of XBI is 66
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

KYMR vs. XBI - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Kymera Therapeutics, Inc. (KYMR) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current KYMR Sharpe Ratio is -0.12, which is higher than the XBI Sharpe Ratio of -0.39. The chart below compares the historical Sharpe Ratios of KYMR and XBI, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

KYMR vs. XBI - Dividend Comparison

KYMR has not paid dividends to shareholders, while XBI's dividend yield for the trailing twelve months is around 0.17%.

TTM20242023202220212020201920182017201620152014
KYMR
Kymera Therapeutics, Inc.		0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
XBI
SPDR S&P Biotech ETF		0.17%0.15%0.02%0.00%0.04%0.20%0.00%0.28%0.24%0.26%0.61%1.07%

Drawdowns

KYMR vs. XBI - Drawdown Comparison

The maximum KYMR drawdown since its inception was -87.51%, which is greater than XBI's maximum drawdown of -63.89%. Use the drawdown chart below to compare losses from any high point for KYMR and XBI.

Loading data...

Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

KYMR vs. XBI - Volatility Comparison

Kymera Therapeutics, Inc. (KYMR) has a higher volatility of 22.77% compared to SPDR S&P Biotech ETF (XBI) at 10.41%. This indicates that KYMR's price experiences larger fluctuations and is considered to be riskier than XBI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Loading data...